Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9157826 | 0.84 | ALDH1A1 (0.51) | ALDH1A1KDM4ETSHRMAPK1HPGD | |
| SCHEMBL9156334 | 0.84 | ALDH1A1 (0.66) | ALDH1A1KDM4ETSHRMAPK1HPGD | |
| SCHEMBL1771514 | 0.83 | CYP1A2 (0.63) | ALDH1A1KDM4ETSHRMAPK1HPGD | |
| SCHEMBL9154974 | 0.83 | ALDH1A1 (0.64) | ALDH1A1KDM4ETSHRMAPK1HPGD | |
| SCHEMBL9157942 | 0.83 | ALDH1A1 (0.50) | CTSVCTSLALDH1A1KDM4ETSHR | |
| SCHEMBL9158331 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KDM4ETSHRMAPK1HPGD | |
| SCHEMBL9160532 | 0.81 | KMT2A (0.52) | ALDH1A1KDM4ETSHRMAPK1HPGD | |
| SCHEMBL12668935 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4ETSHRHPGDHSD17B10 | |
| SCHEMBL12668022 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4ETSHRHPGDHSD17B10 | |
| SCHEMBL12668940 | 0.80 | BID (0.46) | ALDH1A1KDM4EHPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102617-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2013-05-02 | — | — | US | disclosed |
| WO-2011163610-A2 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-1575589-A4 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1133474-B1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7179920-B2 | 3-thia-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7151180-B2 | 3-((hetero)arylthio)-1,2-dihydroquinolin-2-ones such as 3-[(4-aminophenyl)thio]-4-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl)-2(1H)-quinoline; erectile dysfunction and irritable bowel syndrome | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-19 | — | — | US | disclosed |
| US-7145013-B2 | 3-thia-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| US-7132542-B2 | Compounds for the treatment of male erectile dysfunction | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-7049309-B2 | 3-Thia-4-arylquinolin-2-one potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050176763-A1 | 3-Thia-4-arylquinolin-2-one potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-20050124611-A1 | Compounds for the treatment of male erectile dysfunction | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-09 | — | — | US | disclosed |
| US-20050096329-A1 | 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | disclosed |
| US-20050080079-A1 | 3-Thia-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
| US-20050080082-A1 | Potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
| US-20050080105-A1 | [4-(5-Chloro-2-hydroxy-phenyl)-2-oxo-6-trifluoromethyl- 1,2-dihydro-quinolin-3-ylsulfanyl]-acetic acid for example; potassium channel modulators for treating erectile dysfunction and irritable bowel syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
| EP-1133474-A4 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004058260-A1 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1133474-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000034244-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124611-A1 | Compounds for the treatment of male erectile dysfunction | KCNN2, KCNJ11, KCNN1 | CTSV 4850/4885CTSL 4667/4885ALDH1A1 606/4885 |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | RPS4X, RPS4Y1, MRPL21 | CTSV 3739/4885CTSL 3384/4885ALDH1A1 3775/4885 |
| US-20050080079-A1 | 3-Thia-4-arylquinolin-2-one derivatives | KCNQ2, KCNQ1, KCNJ2 | CTSV 4843/4885CTSL 4784/4885ALDH1A1 551/4885 |
| US-20050176763-A1 | 3-Thia-4-arylquinolin-2-one potassium channel modulators | KCNQ2, KCNJ2, KCNQ1 | CTSV 4872/4885CTSL 4813/4885ALDH1A1 762/4885 |
| US-20050080082-A1 | Potassium channel modulators | KCNJ2, KCNJ11, KCNJ1 | CTSV 4870/4885CTSL 4744/4885ALDH1A1 1373/4885 |
| US-20050096329-A1 | 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants | KCNQ2, KCNQ1, KCNQ5 | CTSV 4856/4885CTSL 4776/4885ALDH1A1 966/4885 |
| US-20050080105-A1 | [4-(5-Chloro-2-hydroxy-phenyl)-2-oxo-6-trifluoromethyl- 1,2-dihydro-quinolin-3-ylsulfanyl]-acetic acid for example; potassium channel modulators for treating erectile dysfunction and irritable bowel syndrome | KCNJ2, KCNN2, KCNJ11 | CTSV 4764/4885CTSL 4610/4885ALDH1A1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.